Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- NFX.LSE
- Price
- 0.11
- Stock movement down
- -0.01 (-6.78%)
- Company name
- Nuformix plc
- Exchange
- (LSE ,
- Currency
- GBX )
- Sector
- Healthcare >Biotechnology
- Market cap
- 156.12M
- Ent value
- 156.19M
- Price/Sales
- -
- Price/Book
- 38.06
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -25.98%
- 1 year return
- -46.34%
- 3 year return
- -51.68%
- 5 year return
- -51.96%
- 10 year return
- -
Last updated: 2025-04-12
DIVIDENDS
NFX.LSE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 38.06 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.42B |
| EPS (TTM) | -0.00 |
| FCF per share (TTM) | -0.00 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -45.26K |
| Operating income (TTM) | -861.60K |
| Net income (TTM) | -815.93K |
| EPS (TTM) | -0.00 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 183.52K |
| Net receivables | 98.48K |
| Total current assets | 282.00K |
| Goodwill | 4.02M |
| Intangible assets | 49.29K |
| Property, plant and equipment | 0.00 |
| Total assets | 4.35M |
| Accounts payable | 252.72K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 252.72K |
| Total liabilities | 252.72K |
| Shareholder's equity | 4.10M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -132.32K |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -301.18K |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -19.89% |
| Return on Assets | -18.74% |
| Return on Invested Capital | -19.89% |
| Cash Return on Invested Capital | -7.34% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.11 |
| Daily high | 0.12 |
| Daily low | 0.10 |
| Daily Volume | 21.0M |
| All-time high | 13.75 |
| 1y analyst estimate | 10.00 |
| Beta | 1.00 |
| EPS (TTM) | -0.00 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| NFX.LSE | S&P500 | |
| Current price drop from All-time high | -99.20% | -12.89% |
| Highest price drop | -99.66% | -56.47% |
| Date of highest drop | 22 Nov 2024 | 9 Mar 2009 |
| Avg drop from high | -68.42% | -11.07% |
| Avg time to new high | 90 days | 12 days |
| Max time to new high | 1468 days | 1805 days |
COMPANY DETAILS
Marketcap
156.12M
Marketcap category
Small-cap
Description
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Employees
3
Website
Investor relations
-
SEC filings
CEO
Country
UK
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found